Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Windtree Therapeutics ( (WINT) ).
On August 19, 2025, Windtree Therapeutics Inc. was informed by Nasdaq of its decision to delist the company’s common stock due to noncompliance with Nasdaq Listing Rule 5550(a)(2). Consequently, trading will be suspended on August 21, 2025, and the company expects its stock to trade publicly on the over-the-counter market under the symbol “WINT.” The transition to the OTC Markets will not affect the company’s business or operations, and it will continue to file required reports with the SEC.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Average Trading Volume: 11,202,609
Technical Sentiment Signal: Sell
Current Market Cap: $13.9M
See more data about WINT stock on TipRanks’ Stock Analysis page.